Clinical efficacy of injectable gamithromycin solution for bacterial bovine respiratory disease and drug susceptibility of isolates
2020
Kato, T. ((Yamagata PFAMAA, Yamagata (Japan). Central Livestock Clinic), (Rakuno Gakuen University, Ebetsu, Hokkaido (Japan). School of Veterinary Medicine)) | Ishida, M. | Ito, M. | Shibano, K.
In the present study, we examined the clinical efficacy of injectable gamithromycin (GAM) solution for bovine respiratory disease caused by bacteria and to clarify the associated microbial susceptibility of pathogens. Cattle were randomly assigned to receive a single subcutaneous injection of 6 mg/kg of GAM (n = 121) or 10 mg/kg of tilmicosin (TMS, n = 124). The efficacy was judged based on the symptoms at 3 and 10 days after the treatment. Nasal swab tests were performed to identify pathogens. The clinical efficacy of GAM was 72.5 and 89.2% at 3 and 10 days, respectively, and was equivalent to that of TMS (64.5 and 83.1 % at 3 and 10 days, respectively). There were no adverse events due to either administration. Pasteurella multocida (31.4%, 77/245) and Mycoplasma bovis (19.2%, 47/245) were isolated from the nasal swabs collected prior to the treatment. In the antimicrobial susceptibility test, the minimum 50 and 90% inhibitory concentrations (MICsub(50) and MICsub(90)) of GAM were 0.5 and 4 μg/mL for P. multocida, and 8 and 32 μg/mL for M. bovis, and the MICsub(50) and MICsub(90) of TMS were 4 and 32 μg/mL for P. multocida, and > 128 μg/mL for M. bovis, respectively. Our findings suggest that injectable GAM solution is an effective treatment option for bovine respiratory disease caused by bacteria.
Afficher plus [+] Moins [-]Mots clés AGROVOC
Informations bibliographiques
Cette notice bibliographique a été fournie par Agriculture, Forestry and Fisheries Research Information Technology Center
Découvrez la collection de ce fournisseur de données dans AGRIS